TGIF2LX

Across TCGA pan-cancer cohorts, TGIF2LX Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TGIF2LX data layer compared with 13 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher TGIF2LX Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TGIF2LX expression acts as an unfavorable survival marker.

STAD, HNSC, and OV are the cancer types where TGIF2LX Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	All	0.116	0.546	.006	24	view →
HNSC	DFS	Median	IV	0.156	0.644	.002	24	view →
OV	DFS	Median	II,III,IV	0.193	0.541	.013	18	view →
LUAD	OS	Median	III,IV	0.057	0.680	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

TGIF2LX–STAD (OS)

Open the STAD breakdown →